Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC


An 2018 update to the lung cancer molecular testing guideline says testing for┬áROS1┬árearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics. The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of … Continue reading Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC